Outcomes of Heart Failure Related Hospitalizations During the COVID-19 Pandemic.
| Autor: | Alharbi A; Internal Medicine, University of Toledo, Toledo, USA., Alfatlawi H; Internal Medicine, The University of Toledo Medical Center, Toledo, USA., Mohamed A; Internal Medicine, The University of Toledo Medical Center, Toledo, USA., Mhanna M; Cardiology, University of Iowa, Iowa, USA., Mahmoud M; Cardiology, The University of Toledo Medical Center, Toledo, USA., Elsheik R; Internal Medicine, The University of Toledo Medical Center, Toledo, USA., Moukarbel G; Cardiology, The University of Toledo Medical Center, Toledo, USA., Assaly R; Pulmonary/Critical Care Medicine, The University of Toledo Medical Center, Toledo, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 Mar 30; Vol. 15 (3), pp. e36935. Date of Electronic Publication: 2023 Mar 30 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.36935 |
| Abstrakt: | Background: The incidence and prevalence of heart failure (HF) in the United States has steadily increased in the past few decades. Similarly, the United States has experienced an increase in HF-related hospitalizations which has added to the burden of a resource-stretched healthcare system. With the emergence of the coronavirus disease 2019 (COVID-19) pandemic in 2020, hospitalizations due to the COVID-19 infection sky-rocketed further exacerbating the burden on both patient health and the healthcare system. The focus of this study is to examine how a secondary COVID-19 diagnosis affects the outcome of HF patients, and how a pre-existing diagnosis of heart failure impacts the outcomes of patients hospitalized with COVID-19 infection. Methods: This was a retrospective observational study of adult patients hospitalized with heart failure and COVID-19 infection in the United States in the years 2019 and 2020. Analysis was conducted using the National Inpatient Sample (NIS) database of the Healthcare Utilization Project (HCUP). The total number of patients included in this study from the NIS database 2020 was 94,745. Of those, 93,798 had heart failure without a secondary diagnosis of COVID-19; 947 had heart failure along with a secondary diagnosis of COVID-19. The primary outcome of our study was in-hospital mortality, length of stay, total hospital charges and time from admission to right heart catheterization, which were compared between the two cohorts. Results: Our main study findings are that mortality in HF patients with secondary diagnosis of COVID-19 infection was not statistically different compared to those who were without a secondary diagnosis of COVID-19. Our study findings also showed that length of stay (LOS) and hospital costs in HF patients who had a secondary diagnosis of COVID-19 were not statistically different compared to those who did not have the secondary diagnosis. Time from admission to right heart catheterization (RHC) in HF patients who had a secondary diagnosis of COVID-19 was shorter in heart failure with reduced ejection fraction (HFrEF) but not in heart failure preserved ejection fraction (HFpEF) compared to those without secondary diagnoses of COVID-19. Finally, when evaluating hospital outcomes for patients admitted with COVID-19 infection, we found that inpatient mortality increased significantly when they had a pre-existing diagnosis of heart failure. Conclusion: The COVID-19 pandemic significantly impacted hospitalization outcomes for patients admitted with heart failure. The time from admission to right heart catheterization was significantly shorter in patients admitted with heart failure reduced ejection fraction who also had a secondary diagnosis of COVID-19 infection. When evaluating hospital outcomes for patients admitted with COVID-19 infection, we found that inpatient mortality increased significantly when they had a pre-existing diagnosis of heart failure. Length of hospital stay and hospital charges also were higher for patients with COVID-19 infection who had pre-existing heart failure. Further studies should focus not just on how medical comorbidities like COVID-19 infection, affect outcomes of heart failure but also on how overall strains on the healthcare system, such as pandemics, may affect the management of conditions such as heart failure. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Alharbi et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|